BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31796846)

  • 1. Circulating tumor cells detection in tumor draining vein of breast cancer patients.
    Hattori M; Nakanishi H; Yoshimura M; Iwase M; Yoshimura A; Adachi Y; Gondo N; Kotani H; Sawaki M; Fujita N; Yatabe Y; Iwata H
    Sci Rep; 2019 Dec; 9(1):18195. PubMed ID: 31796846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer.
    Huai J; Cao M; Jiang Y; Yang X; Zhu Y; Si Y; Xu M; Shen C; Han T; Lian X
    Biomed Res Int; 2021; 2021():6388492. PubMed ID: 34901275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter
    Jin L; Zhao W; Zhang J; Chen W; Xie T; Wang L; Fan W; Xie S; Shen J; Zheng H; Hu W; Wei Q; Dong M; Wang Q; Shen J; Liu Y
    Cancer Med; 2020 Mar; 9(5):1638-1647. PubMed ID: 31908156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform.
    Tsutsuyama M; Nakanishi H; Yoshimura M; Oshiro T; Kinoshita T; Komori K; Shimizu Y; Ichinosawa Y; Kinuta S; Wajima K; Sakakibara Y; Yatabe Y; Ito S; Kodera Y
    PLoS One; 2019; 14(2):e0212221. PubMed ID: 30811434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The study of associations between circulating tumor cells and clinicopathologic characteristics in axillary lymph node positive primary breast cancer].
    Zhou Y; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
    Zhonghua Wai Ke Za Zhi; 2014 Jun; 52(6):420-4. PubMed ID: 25219556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
    Förnvik D; Aaltonen KE; Chen Y; George AM; Brueffer C; Rigo R; Loman N; Saal LH; Rydén L
    Breast Cancer Res Treat; 2019 Sep; 177(2):447-455. PubMed ID: 31236809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
    Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
    Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in early breast cancer: A connection with vascular invasion.
    Maltoni R; Fici P; Amadori D; Gallerani G; Cocchi C; Zoli M; Rocca A; Cecconetto L; Folli S; Scarpi E; Serra P; Fabbri F
    Cancer Lett; 2015 Oct; 367(1):43-8. PubMed ID: 26184997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Vetter M; Landin J; Szczerba BM; Castro-Giner F; Gkountela S; Donato C; Krol I; Scherrer R; Balmelli C; Malinovska A; Zippelius A; Kurzeder C; Heinzelmann-Schwarz V; Weber WP; Rochlitz C; Aceto N
    Breast Cancer Res; 2018 Nov; 20(1):141. PubMed ID: 30458879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
    Magbanua MJ; Pugia M; Lee JS; Jabon M; Wang V; Gubens M; Marfurt K; Pence J; Sidhu H; Uzgiris A; Rugo HS; Park JW
    PLoS One; 2015; 10(10):e0141166. PubMed ID: 26496203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.